bioRxiv Science⌕ Search

Biology subjects

Malicdan, M. C.

Publications and source records attributed to Malicdan, M. C..

4 recordsLinked to original sources

Determinants of haplotype phasing accuracy in long-read human genome sequencing

Accurate haplotype phasing is critical for interpreting human genetic variation. Long-read whole-genome sequencing has emerged as a powerful approach for read-based phasing, particularly where parental DNA is absent, yet the determinants of phasing accuracy remain incompletely defined. Here, we evaluate haplotype phasing performance across sequencing technology, reference genome, read length, and coverage depth using Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio) data from two Genome in a Bottle reference samples (HG002 and HG005). In clinically relevant genes, alignment to the T2T-CHM13 (T2T) reference genome improves phasing performance relative to GRCh38, reducing mean gene-level phasing error rates by 3-9-fold. T2T alignment increases phase set NG50 and yields 1.5-2-fold more phased variant pairs. At similar read N50 values, ONT has a higher phasing error rate than PacBio in certain genes. Downsampling demonstrates that phasing error rates plateau at [~]20x coverage. Longer ONT read lengths reduce phasing error rates and extend phase set contiguity. Haplotype-resolved assemblies produce substantially higher phasing error rates than alignment-based phasing, demonstrating the advantage of an alignment-based approach. To enable per-variant-pair confidence assessment, we introduce PhaseQuality, a technology-specific stratification method that assigns confidence tiers to phased variants based solely on sequencing data. PhaseQuality accurately assigns 82-99% of known phasing errors to lower-confidence tiers, reducing error rates among high-confidence pairs to <0.5%. Together, these results demonstrate the primary technical determinants of long-read haplotype phasing accuracy and provide practical benchmarks for optimizing reference genome selection, coverage targets, and read length for long-read sequencing studies.

genomics↗

A POLR3B-variant reveals a Pol III transcriptome response dependent on La protein/SSB

RNA polymerase III (Pol III, POLR3) synthesizes tRNAs and other small non-coding RNAs. Human POLR3 pathogenic variants cause a range of developmental disorders, recapitulated in part by mouse models, yet some aspects of POLR3 deficiency have not been explored. We characterized a human POLR3B:c.1625A>G;p.(Asn542Ser) disease variant that was found to cause mis-splicing of POLR3B. Genome-edited POLR3B1625A>G HEK293 cells acquired the mis-splicing with decreases in multiple POLR3 subunits and TFIIIB, although display auto-upregulation of the Pol III termination-reinitiation subunit POLR3E. La protein was increased relative to its abundant pre-tRNA ligands which bind via their U(n)U-3-termini. Assays for cellular transcription revealed greater deficiencies for tRNA genes bearing terminators comprised of 4Ts than of [&ge;]5Ts. La-knockdown decreased Pol III ncRNA expression unlinked to RNA stability. Consistent with these effects, small-RNAseq showed that POLR3B1625A>Gand patient fibroblasts express more tRNA fragments (tRFs) derived from pre-tRNA 3-trailers (tRF-1) than from mature-tRFs, and higher levels of multiple miRNAs, relative to control cells. The data indicate that decreased levels of Pol III transcripts can lead to functional excess of La protein which reshapes small ncRNA profiles revealing new depth in the Pol III system. Finally, patient cell RNA analysis uncovered a strategy for tRF-1/tRF-3 as POLR3-deficiency biomarkers.

molecular biology↗

Functional modeling of NMIHBA-causing PRUNE1 variants reveals a requirement for its exopolyphosphatase activity.

Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies (NMIHBA) is an autosomal recessive neurodevelopmental and neurodegenerative disorder characterized by global developmental delay and severe intellectual disability. Microcephaly, progressive cortical atrophy, cerebellar hypoplasia and delayed myelination are neurological hallmarks in affected individuals. NMIHBA is caused by biallelic variants in PRUNE1 encoding prune exopolyphosphatase 1. We provide in-depth clinical description of two affected siblings harboring compound heterozygous variant alleles, c.383G>A (p.Arg128Gln), c.520G>T (p.Gly174*) in PRUNE1. To gain insights into disease biology, we biochemically characterized missense variants within the conserved N-terminal aspartic acid-histidine-histidine (DHH) motif and provide evidence that they result in the destabilization of protein structure and/or loss of exopolyphosphatase activity. Genetic ablation of Prune1 results in midgestational lethality in mice, associated with perturbations to embryonic growth and vascular development. Our findings suggest that NMIHBA results from hypomorphic variant alleles in humans and underscore the potential key role of PRUNE1 exopolyphoshatase activity in neurodevelopment.

genetics↗

Deficiency in the endocytic adaptor protein PHETA1/2 impairs renal and craniofacial development

A critical barrier in the treatment of endosomal and lysosomal diseases is the lack of understanding of the in vivo functions of the putative causative genes. We addressed this by investigating a key pair of endocytic adaptor proteins, PH domain containing endocytic trafficking adaptor 1 and 2 (PHETA1/2, also known as FAM109A/B, Ses1/2, IPIP27A/B), which interact with the protein product of OCRL, the causative gene for Lowe syndrome. Here we conducted the first study of PHETA1/2 in vivo, utilizing the zebrafish system. We found that impairment of both zebrafish orthologs, pheta1 and pheta2, disrupted endocytosis and ciliogenesis. In addition, pheta1/2 mutant animals exhibited reduced jaw size and delayed chondrocyte maturation, indicating a role in craniofacial development. Deficiency of pheta1/2 resulted in dysregulation of cathepsin K, which led to an increased abundance of type II collagen in craniofacial cartilages. The abnormal renal and craniofacial phenotypes in the pheta1/2 mutant animals were consistent with the clinical presentations of a patient with a de novo arginine (R) to cysteine (C) variant (R6C) of PHETA1. Expressing the patient-specific variant in zebrafish exacerbated craniofacial deficits, suggesting that the R6C allele acts in a dominant-negative manner. Together, these results provide insights into the in vivo roles of PHETA1/2 and suggest that the R6C variant is contributory to the pathogenesis of disease in the patient.

developmental biology↗